Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more
Molecure S.A. (MOC) - Net Assets
Latest net assets as of March 2025: zł98.21 Million PLN
Based on the latest financial reports, Molecure S.A. (MOC) has net assets worth zł98.21 Million PLN as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł107.45 Million) and total liabilities (zł9.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł98.21 Million |
| % of Total Assets | 91.4% |
| Annual Growth Rate | 38.49% |
| 5-Year Change | -27.89% |
| 10-Year Change | 570.25% |
| Growth Volatility | 99.16 |
Molecure S.A. - Net Assets Trend (2014–2024)
This chart illustrates how Molecure S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Molecure S.A. (2014–2024)
The table below shows the annual net assets of Molecure S.A. from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł103.41 Million | +2.45% |
| 2023-12-31 | zł100.93 Million | -20.18% |
| 2022-12-31 | zł126.45 Million | -10.41% |
| 2021-12-31 | zł141.14 Million | -1.58% |
| 2020-12-31 | zł143.40 Million | +81.23% |
| 2019-12-31 | zł79.13 Million | -3.37% |
| 2018-12-31 | zł81.89 Million | +175.53% |
| 2017-12-31 | zł29.72 Million | +128.50% |
| 2016-12-31 | zł13.01 Million | -15.69% |
| 2015-12-31 | zł15.43 Million | +287.28% |
| 2014-12-31 | zł3.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Molecure S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8084476100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł202.03K | 0.20% |
| Other Comprehensive Income | zł4.09 Million | 3.96% |
| Other Components | zł180.39 Million | 174.45% |
| Total Equity | zł103.41 Million | 100.00% |
Molecure S.A. Competitors by Market Cap
The table below lists competitors of Molecure S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gencurix Inc
KQ:229000
|
$21.11 Million |
|
Columbus
WAR:CLC
|
$21.11 Million |
|
CLARANOVA SE EO 1
F:BV51
|
$21.12 Million |
|
Pudumjee Paper Products Limited
NSE:PDMJEPAPER
|
$21.12 Million |
|
BRIDGETEC Corp
KQ:064480
|
$21.11 Million |
|
Finch Therapeutics Group Inc
PINK:FNCH
|
$21.11 Million |
|
Beta Drugs Ltd.
NSE:BETA
|
$21.10 Million |
|
Abico FS Co Ltd
TWO:8071
|
$21.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecure S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 100,930,175 to 103,407,628, a change of 2,477,453 (2.5%).
- Net loss of 31,287,928 reduced equity.
- New share issuances of 29,716,238 increased equity.
- Other comprehensive income increased equity by 4,049,144.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-31.29 Million | -30.26% |
| Share Issuances | zł29.72 Million | +28.74% |
| Other Comprehensive Income | zł4.05 Million | +3.92% |
| Other Changes | zł-1.00 | -0.0% |
| Total Change | zł- | 2.45% |
Book Value vs Market Value Analysis
This analysis compares Molecure S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.41x to 1.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | zł1.13 | zł6.11 | x |
| 2016-12-31 | zł0.83 | zł6.11 | x |
| 2017-12-31 | zł2.53 | zł6.11 | x |
| 2018-12-31 | zł5.99 | zł6.11 | x |
| 2019-12-31 | zł5.82 | zł6.11 | x |
| 2020-12-31 | zł10.61 | zł6.11 | x |
| 2021-12-31 | zł10.12 | zł6.11 | x |
| 2022-12-31 | zł9.01 | zł6.11 | x |
| 2023-12-31 | zł5.99 | zł6.11 | x |
| 2024-12-31 | zł5.12 | zł6.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecure S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1071.83%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.10x
- Recent ROE (-30.26%) is below the historical average (-7.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -3.62% | -10353.81% | 0.00x | 1.07x | zł-2.10 Million |
| 2016 | -18.64% | -36731.71% | 0.00x | 1.19x | zł-3.73 Million |
| 2017 | -8.09% | -40072.20% | 0.00x | 1.16x | zł-5.38 Million |
| 2018 | -4.61% | -125905.30% | 0.00x | 1.05x | zł-11.97 Million |
| 2019 | -5.25% | -148127.18% | 0.00x | 1.08x | zł-12.07 Million |
| 2020 | 46.20% | 55.28% | 0.80x | 1.04x | zł53.25 Million |
| 2021 | -9.67% | -3410639.00% | 0.00x | 1.07x | zł-27.76 Million |
| 2022 | -10.71% | -180.21% | 0.05x | 1.09x | zł-26.18 Million |
| 2023 | -28.11% | -28373117.00% | 0.00x | 1.11x | zł-38.47 Million |
| 2024 | -30.26% | -1071.83% | 0.03x | 1.10x | zł-41.63 Million |
Industry Comparison
This section compares Molecure S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $81,165,220
- Average return on equity (ROE) among peers: -52.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecure S.A. (MOC) | zł98.21 Million | -3.62% | 0.09x | $21.11 Million |
| Bioceltix S.A. (BCX) | $1.91 Million | -83.78% | 0.69x | $71.31 Million |
| Bioton S.A. (BIO) | $619.64 Million | 5.47% | 0.40x | $42.39 Million |
| Captor Therapeutics S.A. (CTX) | $124.20 Million | -26.23% | 0.16x | $69.93 Million |
| Mabion S.A. (MAB) | $-54.16 Million | 0.00% | 0.00x | $31.56 Million |
| Nanogroup SA (NNG) | $8.37 Million | -119.60% | 1.43x | $12.30 Million |
| Pharmena S.A. (PHR) | $8.98 Million | -45.66% | 0.29x | $2.62 Million |
| PolTREG S.A. (PTG) | $12.83 Million | -6.84% | 0.27x | $16.72 Million |
| Pure Biologics Spólka Akcyjna (PUR) | $7.21 Million | -65.22% | 2.02x | $2.90 Million |
| Ryvu Therapeutics SA (RVU) | $1.50 Million | -131.36% | 5.84x | $100.54 Million |